Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double‐blind, randomized, placebo‐controlled …
SA Stoch, S Zajic, J Stone, DL Miller… - Clinical …, 2009 - Wiley Online Library
Inhibition of cathepsin K (CatK) is a potential new treatment for osteoporosis. In two double‐
blind, randomized, placebo‐controlled phase I studies, postmenopausal female subjects …
blind, randomized, placebo‐controlled phase I studies, postmenopausal female subjects …
Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled …
SA Stoch, S Zajic, J Stone, DL Miller… - Clinical …, 2009 - europepmc.org
Inhibition of cathepsin K (CatK) is a potential new treatment for osteoporosis. In two double-
blind, randomized, placebo-controlled phase I studies, postmenopausal female subjects …
blind, randomized, placebo-controlled phase I studies, postmenopausal female subjects …
[PDF][PDF] Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo …
SA Stoch, S Zajic, J Stone, DL Miller… - CliniCal …, 2009 - researchgate.net
Results In study 1, 49 subjects were randomized, with 37 being assigned the drug and 12
assigned placebo. One subject who had been assigned the drug withdrew from the study. In …
assigned placebo. One subject who had been assigned the drug withdrew from the study. In …
Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled …
SA Stoch, S Zajic, J Stone, DL Miller… - Clinical …, 2009 - pubmed.ncbi.nlm.nih.gov
Inhibition of cathepsin K (CatK) is a potential new treatment for osteoporosis. In two double-
blind, randomized, placebo-controlled phase I studies, postmenopausal female subjects …
blind, randomized, placebo-controlled phase I studies, postmenopausal female subjects …
Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo …
SA Stoch, S Zajic, J Stone, DL Miller… - Clinical …, 2009 - search.ebscohost.com
Inhibition of cathepsin K (CatK) is a potential new treatment for osteoporosis. In two double-
blind, randomized, placebo-controlled phase I studies, postmenopausal female subjects …
blind, randomized, placebo-controlled phase I studies, postmenopausal female subjects …
[引用][C] Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo …
SA STOCH, S ZAJIC, D PANEBIANCO… - Clinical …, 2009 - pascal-francis.inist.fr
Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy
Postmenopausal Women:Two Double-Blind, Randomized, Placebo-Controlled Phase I …
Postmenopausal Women:Two Double-Blind, Randomized, Placebo-Controlled Phase I …
[引用][C] Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo …
SA Stoch, S Zajic, J Stone, DL Miller… - Clinical Pharmacology …, 2009 - cir.nii.ac.jp
Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy
Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies …
Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies …